The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $765,274 five-year Project Grant (CFDA 93.855 Allergy and Infectious Diseases Research) to Boston Medical Center Corporation (BMC) to investigate the impact of defective HIV proviruses on innate immune activation and HIV-associated comorbidities. The research aims to determine if persistent expression of aberrant viral RNAs from defective HIV proviruses in CD4+ T cells and macrophages promotes chronic inflammation, examine differences between HIV-1 and HIV-2 in generating intact proviruses, and explore how DNA damage response mechanisms contribute to establishment of defective proviruses. The findings could provide insights into mechanisms driving persistent inflammation and HIV-related conditions, potentially leading to new therapeutic targets and strategies to improve outcomes for people living with HIV.
Generated 1/28/25, 7:20 AM